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Tatsuo Maeda,10 Taisuke Ito,11 Jun-ichi Sakabe,11 Toshio Heike,12 Torayuki Okuyama,13 Rika Kosaki,14
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‘‘Nagashima-type’’ palmoplantar keratosis (NPPK) is an autosomal recessive nonsyndromic diffuse palmoplantar keratosis characterized
by well-demarcated diffuse hyperkeratosis with redness, expanding on to the dorsal surfaces of the palms and feet and the Achilles
tendon area. Hyperkeratosis in NPPK is mild and nonprogressive, differentiating NPPK clinically from Mal de Meleda. We performed
whole-exome and/or Sanger sequencing analyses of 13 unrelated NPPK individuals and identified biallelic putative loss-of-function
mutations in SERPINB7, which encodes a cytoplasmic member of the serine protease inhibitor superfamily. We identified a major caus-
ative mutation of c.796C>T (p.Arg266*) as a founder mutation in Japanese and Chinese populations. SERPINB7 was specifically present
in the cytoplasm of the stratum granulosum and the stratum corneum (SC) of the epidermis. All of the identified mutants are predicted
to cause premature termination upstream of the reactive site, which inhibits the proteases, suggesting a complete loss of the protease
inhibitory activity of SERPINB7 in NPPK skin. On exposure of NPPK lesional skin to water, we observed a whitish spongy change in
the SC, suggesting enhanced water permeation into the SC due to overactivation of proteases and a resultant loss of integrity of the
SC structure. These findings provide an important framework for developing pathogenesis-based therapies for NPPK.The congenital palmoplantar keratoses (PPKs) are a hetero-
geneous group of diseases. Phenotypic classification of
hereditary PPKs is based mainly on the specific mor-
phology and distribution of the hyperkeratosis, the
presence or absence of associated features, and the
inheritance pattern and is assisted by additional criteria
such as the presence of skin lesions in areas other than
the palms and soles, the age at onset of the hyperkeratosis,
the severity of the disease process, and histopathological
findings.1
‘‘Keratosis palmoplantaris Nagashima’’2 or ‘‘Nagashima-
type’’ PPK (NPPK)3 has been proposed as a clinical entity
included within the diffuse hereditary PPKs without asso-
ciated features.1 A familial case of two siblings was first re-
ported as a distinct clinical type of PPK in 1989.2,4 Because
Nagashima briefly described this type of hereditary PPK in
the Japanese literature in 1977,5 the name ‘‘keratosis pal-
moplantaris Nagashima’’ was proposed.2 Although about
20 cases of Japanese individuals with NPPK have been re-
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The Americanentity was not described in detail in the English language
literature until 2008.3
An autosomal recessive trait has been suggested in
NPPK.2,3 The clinical features of NPPK are characterized
by well-demarcated reddish and diffuse palmoplantar
hyperkeratosis that extends to the dorsal surfaces of the
hands, feet, inner wrists, ankles, and the Achilles tendon
area.2–6 Involvement of the elbows and knees and high fre-
quencies of hyperhidrosis on palms and soles have been
noted.3 Clinical observations revealed no differences be-
tweenmales and females, no seasonal change, and no asso-
ciation with squamous cell carcinoma or any other malig-
nancy. Althoughmild Tcell infiltration in the affected skin
area has been reported,7 the pathophysiology of the skin
redness and hyperkeratosis are still uncharacterized.
An autosomal recessive trait, transgressive diffuse hyper-
keratosis, and the absence of associated features are also
characteristic of Mal de Meleda (MDM [MIM 248300]),8
PPK Gamborg Nielsen (Norrbotten recessive type PPK
[MIM 244850]),9,10 and acral keratoderma.11 These other-8582, Japan; 2Keio-Maruho Laboratory of Skin Barriology, Keio University
l Research, Keio University School of Medicine, Tokyo 160-8582, Japan;
ne, Tokyo 160-8582, Japan; 5Department ofMaternal-Fetal Biology, National
n; 6KOSE´ Corporation, Tokyo 174-0051, Japan; 7Department of Molecular
of Diagnostic Pathology, Keio University Hospital, Tokyo 160-8582, Japan;
Kyoto 606-8507, Japan; 10Department of Dermatology, Tokyo Medical Uni-
iversity School of Medicine, Hamamatsu 431-3192, Japan; 12Department of
an; 13Department of Laboratory Medicine, National Center for Child Health
National Center for Child Health and Development, Tokyo 157-8535, Japan;
582, Japan; 16Laboratory of GeneMedicine, Keio University School of Med-
al Research Institute for Child Health and Development, Tokyo 157-8535,
okyo 143-8540, Japan; 19Department of Dermatology, National Center for
y of Human Genetics. All rights reserved.
Journal of Human Genetics 93, 945–956, November 7, 2013 945
diffuse PPKs show more severe and more progressive fea-
tures than does NPPK, such as thick hyperkeratosis, lead-
ing to flexion contractures (MDM) and constricting bands
surrounding the digits (MDM, PPK Gamborg Nielsen, and
acral keratoderma), occasionally resulting in spontaneous
amputation (MDM and acral keratoderma).1 NPPK shows
only mild and nonprogressive hyperkeratosis and does
not show flexion contractures or constricting bands.
Thus, NPPK is distinguishable clinically from these other
PPKs. Mutations in the coding region of the SLURP1
(MIM 606119) have been identified in MDM but not in
NPPK, suggesting that MDM and NPPK are genetically
distinct diseases.3,12
To identify gene mutations responsible for NPPK, we
performed whole-exome sequencing in three unrelated
Japanese NPPK individuals (KDex8 [II-1 of family 1 in
Figure 1A], KDex14 [II-2 of family 2], and KDex20 [II-3 of
family 3]) who showed the characteristic symptoms of
NPPK; Figures 1B and 1C; see Figure S1 available online.
Clinical features are summarized in Table 1. The major
clinical differentiating points by which we diagnosed these
individuals with NPPK among the diverse hereditary PPKs
without associated features are summarized in Table 2. The
study was conducted after obtaining written informed
consent according to the guidelines of the Institutional
Review Board of Keio University School of Medicine,
National Center for Child Health and Development, Kyoto
University, and Tokyo Medical University in accordance
with the Helsinki guidelines.
Whole-exome sequencing and data analyses were per-
formed as described previously.13 Whole-exome sequenc-
ing produced approximately 100,000,000 paired reads
per sample, approximately 80% of which were mapped
to the hs37d5 exon region of the human genome sequence
assembly.14 The average coverage of the exonic region was
87.53, with more than 93.2% of targeted bases covered at
103 reads. No SLURP1 mutation (Refseq: NM_020427.2)
was identified in any of the three NPPK individuals. A
genome informatics study found 693, 677, and 747 allelic
variants in three NPPK individuals (KDex8, 14, and 20,
respectively), showing a minor allele frequency of less
than 1% in the 1092 individuals from the 1000 Genomes
Project.14 Because NPPK is possibly inherited in an auto-
somal recessive manner,2,3 the causative mutation was ex-
pected to be a homozygous or compound heterozygous
variant shared by the affected individuals but absent or
found only in a heterozygous manner in the control
cohort. Among the identified variants, only mutations in
the SERPINB7 (MIM 603357) fulfilled these requirements,
suggesting a causative role in NPPK (Table 1).
SERPINB7 consists of eight exons, with three distinct
transcription start sites (exons 1a–c; Figure 2A). The start
codon is located within exon 2, and the termination codon
within exon 8 (Figure 2A). The SERPINB7 transcript
(RefSeq: NM_001040147.2) encodes a 380 amino-acid
protein. Mutations identified by whole-exome sequencing
were confirmed by Sanger sequencing by using the primers946 The American Journal of Human Genetics 93, 945–956, Novembin Table S1 (Figure 2B). A nonsense mutation encoding a
c.796C>T alteration (p.Arg266*) in the last exon of the
SERPINB7 was found in all three NPPK individuals.
KDex20 was homozygous for the c.796C>T nonsense
mutation. KDex8 was a compound heterozygote of a
maternal c.796C>T mutation and a paternal small
indel mutation of c.218_219delAGinsTAAACTTTACCT
(c.218_219del2ins12) at the end of exon 3, predicted to
lead to a premature stop codon (p.Gln73Leufs*17).
KDex14 was a compound heterozygote of a maternal
c.796C>T mutation and a paternal mutation of
c.455-1G>A in the splice acceptor site upstream of exon
6 of SERPINB7, whichwas also predicted to lead to a prema-
ture stop codon (p.Gly152Valfs*21) at chromosome 18:
61465837 in the hs37d5 human genome sequence.14
To confirm mutations in SERPINB7 as a cause of NPPK,
we analyzed ten additional unrelated NPPK individuals.
The clinical manifestations of these individuals are pre-
sented in Table 1. Sanger sequencing failed to detect a
mutation in SLURP1 in any of the ten individuals by using
methods described previously.3 When the entire coding
region of SERPINB7 was analyzed by Sanger sequencing
with the primers in Table S1, five of the ten individuals
were homozygous for the c.796C>T mutation, four were
compound heterozygotes of the c.796C>T and c.218_219
del2ins12 mutations, and one was a compound heterozy-
gote of the c.796C>Tand c.455-1G>Amutations (Table 1).
These results confirmed that mutations in SERPINB7 are a
major cause of NPPK and that c.796C>T and c.218_219
del2ins12 are major mutations for NPPK in a Japanese
population.
From our clinical experience, NPPK is much more com-
mon than other types of hereditary PPKs in Japan,
although no statistical analysis has been reported. NPPK
has not been recognized as a clinical entity within PPKs
in Western populations, probably because it is rare. Next,
we evaluated the variant databases of the cohort of
1,092 individuals in the 1000 Genomes Project14 to esti-
mate the frequency of SERPINB7 mutations classified by
ethnicity. The nonsense mutation of c.796C>T was identi-
fied as an SNP (rs142859678) with a minor allele frequency
of 0.4% and found in a heterozygous manner in two of 89
Japanese individuals, four of 97 Han Chinese individuals
from Beijing, and two of 100 Han Chinese individuals
from southern China. On the other hand, the c.796C>T
mutation was not found in any of 806 non-Asian individ-
uals, suggesting that the c.796C>T mutation is a founder
mutation causing NPPK in Asian populations. We also
found another putative causative mutation, c.336þ2T>G
(an SNP of rs201433665), in one of 97 Han Chinese indi-
viduals from Beijing in a heterozygous manner. Other
mutations found in this study were not identified in the
1,092 individuals.
From these results, the prevalence rate of NPPK was
estimated as 1.2/10,000 in Japanese populations and
3.1/10,000 in Chinese populations. In contrast, no puta-
tive causative mutation (nonsense, missense, insertion,er 7, 2013
Figure 1. Family Pedigrees and Skin Manifestations of the Probands with NPPK
(A) Pedigrees for the families in which exome sequencing and analyses were performed on the probands (KDex8, KDex14, and KDex20).
Segregation of the mutations identified in each pedigree is shown.
(B) Skin manifestations of the proband KDex14.
(C) Hematoxylin and eosin staining of the plantar epidermis of the proband KDex8. Scale bars represent 100 mm.deletion, or exon-intron boundary mutation) was identi-
fied in 806 individuals of non-Asian origin in the 1000
Genomes Project.14 We further searched causative muta-
tions in European-American and African-American popu-The Americanlations by using the NHBLI Exome Variant Server and
found only one putative causative mutation, c.309delT
in the exon 4 (1 of 12,517 alleles), predicted to lead to
a premature stop codon (p.Phe103Leufs*33). Thus, theJournal of Human Genetics 93, 945–956, November 7, 2013 947
Table 1. SERPINB7 Mutations and Clinical Phenotypes in Individuals with NPPK
Affected Individual Gender / Age
Allele 1 Allele 2
Onset
Other Involved
Areas HyperhidrosisBase Change
Amino Acid
Change Segregation Base Change Amino Acid Change Segregation
Homozygous Mutations
KDex20a F/10 c.796C>T p.Arg266* Paternal c.796C>T p.Arg266* Maternal At birth Knees þ
KDex55 F/2 c.796C>T p.Arg266* Paternal c.796C>T p.Arg266* Maternal Early infancy  
KDex62 M/31 c.796C>T p.Arg266* NA c.796C>T p.Arg266* NA 1 week Knees þ
KDex72 F/5 c.796C>T p.Arg266* Paternal c.796C>T p.Arg266* Maternal At birth Knees and elbows þ
KDex79 M/31 c.796C>T p.Arg266* NA c.796C>T p.Arg266* NA At birth Knees and elbows þ
KDex90 M/14 c.796C>T p.Arg266* Paternal c.796C>T p.Arg266* Maternal 9-10 years Knees and elbows þ
Compound Heterozygous Mutations
KDex8a M/38 c.796C>T p.Arg266* Maternal c.218_219del2ins12 p.Gln73Leufs*17b Paternal At birth Knees and elbows þ
KDex59 F/16 c.796C>T p.Arg266* Paternal c.218_219del2ins12 p.Gln73Leufs*17b Maternal At birth  þ
KDex60 F/30 c.796C>T p.Arg266* Paternal c.218_219del2ins12 p.Gln73Leufs*17b Maternal At birth Knees þ
KDex64 F/28 c.796C>T p.Arg266* Paternal c.218_219del2ins12 p.Gln73Leufs*17b Maternal 2 years  þ
KDex66 F/64 c.796C>T p.Arg266* NA c.218_219del2ins12 p.Gln73Leufs*17b NA Early infancy  
KDex14a M/20 c.796C>T p.Arg266* Maternal c.455-1G>A p.Gly152Valfs*21b Paternal At birth Knees and elbows þ
KDex58 M/51 c.796C>T p.Arg266* NA c.455-1G>A p.Gly152Valfs*21b NA 5–6 years Knees and elbows þ
Abbreviations: M, male; F, Female; NA, not available; c.218_219del2ins12, c.218_219delAGinsTAAACTTTACCT.
aWhole-exome sequencing performed.
bPredicted from genomic sequences.
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Table 2. Major Clinical Differentiating Points among Diffuse Hereditary Palmoplantar Keratoses without Associated Features
Types Vo¨rner37 Unna-Thost38,39 Greither40 Sybert41 Bothnian31 Mal de Meleda8 Nagashima2,3
Gamborg
Nielsen9,10
Acral
Keratoderma11
Other names Diffuse
Epidermolytic
PPK
Diffuse
Nonepidermolytic
PPK
Progressive PPK Keratosis
Palmoplantaris
Transgradiens of
Siemens
MIM number 144200 600962 144200 600231 248300 244850
Mode of inheritance AD AD AD AD AD AR AR AR AR
Responsible gene KRT1,42
KRT943,44
KRT145 KRT146 Unknown AQP532,33 SLURP112 SERPINB7a Unknown Unknown
Prevalence rate 4.4/100,000
populations in
Northern
Ireland47
Clinical entity in
doubt1,48,49
Rare Rare Rare Relatively common in
the island of Meleda.
1/100,000 in general
populations50
1.2/10,000 in
Japana, 3.1/10,000
in Chinaa
Rare Rare
Age of onset Within the first
year of life
Within the first
2 years of life
Ages 8 to 10 Within the first
year of life
During childhood,
not as early as
during the first
year of life
Early infancy Mostly within the
first year of life
Pathologic findings Epidermolytic
hyperkeratosis
Nonepidermolytic Nonepidermolytic Nonepidermolytic Nonepidermolytic Nonepidermolytic Nonepidermolytic Nonepidermolytic Nonepidermolytic
Hyperkeratosis Thick Thick Thick Thick Mild to thick Severe Mild Thick Thick
Transgrediens   þ þ þ þ þ þ (1 of 4) þ
Hyperhidrosis   þ Not described þ þ þ Not described Not described
Whitish change upon
water exposure
    þ  þ  
Development on
other areas
  Elbows, knees,
flexural areas, and
Achilles tendon
Natal cleft, groin,
elbows, knees,
posterior aspects
of forearms, and
anterior aspects
of legs
 Knees and elbows,
perioral erythema,
and periorbital
erythema
Knees, elbows,
and Achilles
tendon area
Only knuckle pads
on the dorsa of the
fingers
Knees, elbows,
ankles, Achilles
tendon area
Constricting bands   þ þ  þ  þ þ
Spontaneous
amputation
  þ þ  Occasionally  Not described þ
Flexion contractures      þ   
Abbreviations: AD, autosomal dominant inheritance; AR, autosomal recessive inheritance.
aThis study.
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Figure 2. Genomic Organization of
SERPINB7, Reactive Site Loop for Protease
Inhibitory Activity of the SERPINB7 Pro-
tein, and Location of NPPK-Causing
Mutations
(A) Schematic presentation of the genomic
structure of SERPINB7 (lower) and its en-
coded protein (middle), SERPINB7. The
gray box indicates the reactive site loop
indispensable for protease inhibitory ac-
tivity of SERPINB7. Open and filled boxes
indicate exons of untranslated regions
and coding regions, respectively. The posi-
tions of SERPINB7 mutations identified in
this study are indicated. The immunogen
of the anti-SERPINB7 polyclonal antibody
is shown at the top.
(B) Heterozygous or homozygous mutated
sequences of affected individuals (KDex8,
KDex14, and KDex20) compared with the
corresponding wild-type sequences. The
base and amino acid sequences are shown.
The intron-exon junctions are shown
with red dotted lines. Intron and exon
sequences are shown in lower case and
upper case, respectively.
Abbreviations are as follows: c.218_219
del2ins12, c.218_219delAGinsTAAACTTT
ACCT.prevalence rate of NPPK in non-Asian populations was
~0.5/100,000,000. These results well explain why NPPK
is so common in PPKs in Japanese populations but has
not been reported from non-Asian countries.
Serpins were originally identified as serine protease in-
hibitors. Serpin molecules are evolutionarily old because
even bacteria and Archaea possess them.15–17 Most
serpins identified to date possess protease inhibitory
activity, although their protease targets are now known
not to be restricted to serine proteases.16,17 Serpins form
covalent complexes with target proteases to inhibit
protease activity irreversibly. Human serpins have been
divided into nine clades (A–I) by phylogenetic ana-
lyses.15,18 Several congenital diseases have been reported
to be caused by deficiencies in the protease inhibitory
function of serpins—for example, plasminogen activator
inhibitor-1 deficiency (MIM 613329) with mutations
in SERPINE1 (MIM 173360)19—or to be caused by poly-
merization and accumulation of mutated serpins, for
example, familial encephalopathy with neuroserpin in-
clusion bodies (MIM 604218) with mutations in SERPINI1
(MIM 602445).20950 The American Journal of Human Genetics 93, 945–956, November 7, 2013SERPINB7 is located on chromo-
some 18q21.3, forming a cluster of
clade-B serpin genes.18 Clade-B ser-
pins are intracellular serpins, possibly
protecting cells from exogenous
and endogenous protease-mediated
injury.18 The protease-inhibitory ac-
tivity of serpins is dependent on the
reactive site loop to form a covalentbond with target proteases.16 The center of the reactive
site loop (P1–P1’) is located at amino acids 347–348 of
SERPINB7,16 and the entire region of the reactive site
loop (P17–P50, corresponding to the amino acid region
331–352 of SERPINB7) is predicted to be absent in all of
the mutant proteins (Figure 2A). Thus, all of the mutations
identified in this study presumably result in a complete
loss of the protease inhibitory activity of SERPINB7.
SERPINB7 was originally described as being expressed in
kidney mesangial cells and was named MEGSIN.21 How-
ever, no renal manifestation has been identified in NPPK
individuals. A recent report using a bacterial artificial
chromosome transgene expressing Cre in mice under the
control of Serpinb7 regulatory elements showed specific
expression of Cre in cornified stratified epithelial cells,
but not in kidney mesangial cells,22 suggesting that
Serpinb7might be specifically expressed in epidermal kera-
tinocytes in mice. Thus, we next analyzed the expression
of SERPINB7 in human skin. We used a commercial poly-
clonal antibody (HPA024200; Sigma-Aldrich) raised against
a peptide corresponding to the amino acid 203–334
region of human SERPINB7 (Figure 2A). To characterize
Figure 3. SERPINB7 Localization in the
Epidermis and Immunohistochemical
Analysis of the Affected Skin
(A) Investigation of the anti-SERPINB7
antibody. GST-fused recombinant full-
length human SERPINB7 (lanes 1 and 3)
and GST-fused recombinant p.Arg266*
mutant (lanes 2 and 4) were analyzed by
electrophoresis with Coomassie Brilliant
Blue staining (lanes 1 and 2) or with
immunoblotting with the anti-SERPINB7
rabbit polyclonal antibody (lanes 3 and 4).
Scale bars indicatemolecular weights (kDa).
(B) Immunohistochemistry of SERPINB7
in plantar skin of a healthy control. Upper
panel shows SERPINB7 in the stratum
granulosum (arrow) and in the upper part
of the stratum corneum (arrowhead).
Lower panel shows the intracellular distri-
bution of SERPINB7 in the stratum granu-
losum. Scale bars represent 100 mm. Inset
in the lower panel shows stratum granulo-
sum cells and intercellular spaces at higher
magnification (scale bar represents 50 mm).
(C) Immunohistochemistry of SERPINB7
in the hyperkeratotic plantar skin of NPPK
individual of KDex8. Scale bar represents
100 mm.
(D) Immunohistochemistry of SERPINB7
in facial and abdominal skin sections of
a healthy control. Scale bars represent
100 mm.
(E) Immunohistochemistry of epidermal
differentiation-related proteins in plantar
skin of a healthy control (upper panels)
and a NPPK individual (KDex8; lower
panels). Scale bar represents 100 mm.the antibody, we performed immunoblotting against
GST-fused full-length human SERPINB7 and GST-fused
p.Arg266* mutant that were produced in Escherichia coli
BL21(DE3) by using the pGEX 5X-1 vector (GE Healthcare)
in inclusion bodies and purified bywashingwith 1%Triton
X-100 and 4M urea. The purified proteins showedmolecu-
lar weights of ~62 kDa and ~50 kDa in SDS-PAGE analysis,
respectively (Figure 3A). In immunoblotting analysis, the
anti-SERPINB7 antibody recognized both the GST-fused
full-length SERPINB7 and GST-fused p.Arg266* mutant
(Figure 3A). The immunosignals for the full-length
SERPINB7 were stronger than those for the truncated
p.Arg266* mutant, suggesting that this polyclonal anti-
body includes antibodies against peptides corresponding
to both the amino acid 203–265 region and the 266–334
region of human SERPINB7 (Figure 2A).
Using this antibody, we performed an immunohisto-
chemical analysis of paraffin wax-embedded sections of
healthy human skin and NPPK skin, with antigen retrieval
with 15 min boiling in a microwave oven in 100 mM Tris-
HCl and 1mM EDTA buffer (pH 9.0), immunosignal detec-
tion with ImmPRESS kit and NovaRed substrates (Vector
Laboratories), and counterstaining with methyl green
(Wako Pure Chemical). The immunosignals of the anti-
body were specifically detected from the stratum granulo-
sum and from the upper part of the SC in healthy controlThe Americanplantar skin (Figure 3B). No signal was detected from the
lower part of the SC, probably because the tightly packed
intracorneocyte proteinaceous structure prevents access
of the antibody to the antigen. When the stratum granulo-
sum was observed at higher magnification, signals were
observed in the cytoplasm, with a mild concentration to
the apical side of the stratum granulosum cells
(Figure 3B). In NPPK individuals, the immunosignals of
the stratum granulosum and the SC were markedly dimin-
ished (KDex8, a compound heterozygote of the c.796C>T
and c.218_219del2ins12 mutations; Figure 3C. For other
affected individuals, data are not shown or skin biopsies
were not performed). Thus, the immunosignals observed
in healthy control plantar skin were considered to repre-
sent the distribution of SERPINB7. Some nuclear staining
was observed in both the healthy control skin and the
NPPK skin, which was considered to be nonspecific back-
ground (Figures 3B and 3C). Weak cytoplasmic immuno-
signals were observed in the NPPK skin, which were
considered to be due to the p.Arg266* mutant of SERPINB7
or nonspecific background (Figure 3C).
To clarify whether SERPINB7 expression was limited to
the palmoplantar area of the skin,we immunostained facial
and abdominal skin sections of healthy controls. SERPINB7
immunosignals were specifically detected from the stratum
granulosum and the SC in facial and abdominal epidermisJournal of Human Genetics 93, 945–956, November 7, 2013 951
(Figure 3D), suggesting that SERPINB7 is expressed in the
epidermis of the whole body.
Next, we investigated whether loss of functional
SERPINB7 affected epidermal differentiation by using
NPPK skin. In NPPK plantar skin, hematoxylin and eosin
staining showed acanthosis and orthohyperkeratosis (Fig-
ure 1C), as described previously.3 The localization of
epidermal differentiation markers, loricrin, involucrin,
and filaggrin, which were detected with anti-loricrin
(ab24722; Abcam), anti-involucrin (clone SY5; Sigma
Aldrich), and anti-filaggrin (clone FLG01; Thermo Scienti-
fic) antibodies, respectively, showed no major keratinocyte
differentiation defect in NPPK skin (Figure 3E). Transmis-
sion electron microscopic studies of NPPK skin failed to
show any major defect in the stratum granulosum or the
SC (data not shown).
Loss of functional SERPINB7 might induce overactiva-
tion of target proteases in the stratum granulosum and
the SC. Because no apparent change was observed in the
stratum granulosum except for thickening, we reinvesti-
gated the skin phenotype of NPPK, looking especially for
any finding of changes in the SC. We found that the
NPPK skin showed a whitish spongy appearance within
10 min of water exposure specifically in the reddish hyper-
keratotic area (Figure 4A). The wrinkling of palms that is
observed after water exposure in cystic fibrosis (MIM
219700)23,24 was not apparent, even after 30 min of
water exposure (Figure 4A). These phenotypes suggested
enhanced water permeation into the surface of the SC in
NPPK lesional skin.
Thus, we next performed a transepidermal water loss
(TEWL) analysis prior to and after water exposure in three
NPPK individuals and three healthy controls. TEWL was
measured at the lesional and nonlesional skin of dorsal
hands and inner wrists in each NPPK individual and at
the corresponding skin area in each healthy control with
a Vapo Scan AS-VT100RS (Asahi Biomed) at room temper-
ature (20C–22C) and 40%–60% humidity to avoid the
effects of hyperhidrosis. The mean TEWL value was calcu-
lated from measurements of at least eight different points
under each skin condition. Before water exposure, the
mean TEWL values were higher in the lesional skin of
NPPK individuals than in the nonlesional skin of NPPK
individuals or the corresponding skin area of normal
healthy controls (Figure 4B), when analyzed by using the
Tukey-Kramer multiple-comparisons test with the Prism
software (ver. 6; GraphPad Software). Next, the hands of
NPPK individuals and healthy controls were immersed in
water at 37C for 30 min. After water exposure, TEWL
values were significantly elevated in all skin conditions
in all NPPK skin and in all healthy control skin (data not
shown), and the mean TEWL values were significantly
elevated on water exposure in any skin condition (Fig-
ure 4B) when analyzed with Student’s t test with the Prism
software.
After water exposure, the mean TEWL values were
higher in the lesional skin of NPPK individuals than in952 The American Journal of Human Genetics 93, 945–956, Novembthe nonlesional skin of NPPK individuals or the corre-
sponding skin areas of healthy controls (Figure 4B) when
analyzed with the Tukey–Kramer multiple-comparisons
test. Because the TEWL instrument measures water evapo-
ration from the skin surface, the TEWL values after water
exposure might correspond mostly to water evaporation
from water-swollen SC. Thus, these results suggest that
water permeation into the SC is specifically facilitated in
NPPK lesional skin.
Here, we identified that loss-of-function mutations in
SERPINB7 cause NPPK and established NPPK genetically
as a distinct clinical entity within hereditary diffuse PPKs
without associated features. While SERPINB7 was consid-
ered to be expressed in the epidermis of the whole body,
the affected skin area of NPPK is limited to hands, feet,
knees, and elbows, the reason for which remains un-
known. Such limitations in the affected skin area with a
deficiency of gene products that are ubiquitously expressed
in the epidermis have been observed in several other types
of PPK: Vohwinkel syndrome (MIM 124500), caused by
mutations in GJB2 (MIM 121011),25 and type I striate
PPK (MIM 148700), caused by mutations in DSG1 (MIM
125670).26 The effects on the knees and elbows in
NPPK suggest that chronic exposure to mechanical stress
might have a role in the development of NPPK skin
lesions, and the lesions in NPPK are limited to chronic
mechanical stress-exposed areas of the skin. Thus,
SERPINB7 might inhibit mechanical stress-induced prote-
ases and protect keratinocytes or corneocytes from prote-
ase-mediated cellular damage.
Our findings suggest that NPPK is a genetic dermatosis
caused by a deficiency of an intracellular protease inhibi-
tor. Deficiencies of the protease inhibitors, LEKTI, encoded
by SPINK5 (MIM 605010), and cystatin A, encoded by
CSTA (MIM 184600), have been reported in Netherton syn-
drome (MIM 256500)27 and exfoliative ichthyosis (MIM
607936),28 respectively. In Netherton syndrome, overacti-
vation of secreted extracellular proteases, kallikreins, has
been suggested to induce overdesquamation via excessive
degradation of cell adhesion molecules in the SC29 and
skin inflammatory responses through thymic stromal
lymphopoietin expression, mediated by unregulated acti-
vation of protease-activated receptor-2.30 In exfoliative
ichthyosis, defects in desmosome-mediated cell-cell adhe-
sion in the lower levels of the epidermis have been sug-
gested to cause coarse peeling of skin on the palms and
soles.28 However, the precise pathophysiology or protease
overactivation induced by the loss of cystatin A has not
yet been characterized.
As corneocytes lose the cell membrane on cornification,
it is unclear whether SERPINB7 is held within corneocytes
at the SC. But the phenotype of NPPK differs completely
from that of Netherton syndrome because desquamation
is rather prolonged in the erythematous hyperkeratotic
area in NPPK, suggesting that the target proteases of
SERPINB7 are unlikely to be associated with the desquama-
tion process. Here, we observed a whitish spongy changeer 7, 2013
Figure 4. Changes upon Water Exposure in NPPK Lesional Skin
(A) Clinical phenotype of the hands of the proband (KDex8) prior to water exposure (upper left panel) and after 10 min water exposure
(upper right panel), and the clinical phenotype of the hands of the proband (KDex14) after 30 min water exposure: the palm (lower left
panel), inner wrist (lower middle panel), and dorsa of the thumb (lower right panel).
(B) Means of TEWL values prior to water exposure and after 30 min of water exposure in the lesional skin and nonlesional skin of NPPK
individuals (n¼ 3; KDex8, KDex14, and KDex79) and in the corresponding skin area of healthy controls (n¼ 3). In each skin condition,
the means of TEWL were compared upon water exposure (lower lines). The means of TEWL were compared between lesional and non-
lesional skin of NPPK individuals and the corresponding skin area of healthy controls before water exposure (upper black lines) and after
water exposure (upper red lines).
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in the SC on exposure to water in the lesional skin of NPPK.
This change is caused by a loss of integrity in the SC struc-
ture, probably due to overactivation of target proteases of
SERPINB7. Such a whitish change in the skin upon water
exposure has been reported in an autosomal-dominant
Bothnian-type PPK (MIM 600231) with mutations in
AQP5 (MIM 600442),31–33 and in the aquagenic kerato-
derma associated with cystic fibrosis with mutations in
CFTR (MIM 602421),23,24 but the pathophysiology of the
whitish changes might differ among these diseases.
Together with the strong immunosignals of SERPINB7 in
the SC, we propose that loss of functional SERPINB7 in-
duces overactivation of intracorneocyte proteases specif-
ically in the affected skin area, which induces degradation
of the integrated proteinaceous structure of the corneo-
cytes and facilitates water permeation into the SC. Addi-
tional functional assays and molecular biological analyses
are required to investigate the changes in the water repel-
lant properties of the SC surface in NPPK skin.
Various proteases are present in the stratum granulosum
and the SC34–36. Additionally, the epidermis is attacked by
various exogenous proteases—originating from bacteria,
fungi, virus, pollen, and house dust mites—and endoge-
nous proteases, originating from infiltrating cells.35
Appropriate control of the activity of these proteases by
endogenous protease inhibitors is likely important in
maintaining skin homeostasis. Our discovery of loss-of-
function mutations in SERPINB7 in NPPK should provide
insights into the functions and regulatory mechanisms of
proteases and protease inhibitors in the epidermis. Future
studies will aim to identify the target proteases of SERPINB7
in the steady state and in mechanically stressed states. It is
also important to understand the pathophysiology of the
putative protease overactivation in NPPK skin; that is,
how the proteinaceous structure of the SC and integrity
of the SC barrier are affected and whether the reddish
hyperkeratosis and inflammatory cell infiltrations are sec-
ondary changes via augmented external stimuli through
protease-mediated damage to the SC or direct effects of
intraepidermal overactivation of proteases. The develop-
ment of specific protease inhibitors mimicking SERPINB7
might allow pathogenesis-based therapies for NPPK.Supplemental Data
Supplemental Data includes one figure and one table and can be
found with this article online at http://www.cell.com/AJHG/
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